Cytosorbents
Monmouth Junction
About Cytosorbents
CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $112.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: nasdaq:CTSO
- Website: cytosorbents.com
- Phone: 7323298650
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cytosorbents-7312 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.